Authored By: Sarah
16 Aug 2024

 Recombinant Proteins Market Size to grow by USD 778.5 million between 2024-2028

According to a research report “ Recombinant Proteins Market” by Application (Biotechnology research, Drug discovery and development, Biopharmaceutical production, Others) End-user (Pharma and biotechnology companies, Academic and research institutes, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 778.5 million, at a CAGR of 10.23% during the forecast period. In the healthcare industry, recombinant proteins play a pivotal role in treating major chronic diseases such as cancer, cardiovascular diseases, endocrine disorders, and viral infections. According to the World Health Organization, cancer is the second leading cause of death worldwide, accounting for approximately one in six global deaths. Additionally, cardiovascular diseases, which are caused by factors such as high blood pressure, high cholesterol, obesity, unhealthy diet, physical inactivity, and tobacco use, are on the rise. The prevalence of these chronic conditions is projected to surge during the forecast period, consequently driving the demand for recombinant proteins as effective therapeutic solutions. Furthermore, neurological disorders, which are also prevalent, will contribute to the market growth..

Browse market data tables, figures, and in-depth TOC on “Recombinant Proteins Market” by Application (Biotechnology research, Drug discovery and development, Biopharmaceutical production, Others) End-user (Pharma and biotechnology companies, Academic and research institutes, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

By Application, the Biotechnology research segment is projected to dominate the market size in 2024

The recombinant proteins market represents a significant business opportunity for biotechnology companies, as the demand for these proteins continues to grow in various industries, including pharmaceuticals, agriculture, and research. Recombinant proteins offer several advantages, such as improved consistency, increased yield, and reduced production costs, making them a preferred choice over traditional methods. Market growth is driven by factors such as increasing research and development activities, regulatory approvals, and technological advancements.

By End-user, Pharma and biotechnology companies  segment is expected to hold the largest market size for the year 2024

The recombinant proteins market represents a significant business opportunity for biotechnology companies, as the demand for these proteins continues to grow in various industries. Recombinant proteins are produced using biotechnological methods, offering advantages such as consistent quality, large-scale production, and the ability to produce proteins that are difficult or impossible to obtain through traditional methods. Key applications include pharmaceuticals, agriculture, and diagnostics, with the market expected to expand due to increasing research and development efforts and regulatory approvals.

North America is forecasted to hold the largest market size by region in 2024

The Recombinant Proteins Market represents a significant business opportunity for biotechnology companies, driven by the increasing demand for these proteins in various industries. These proteins, produced through genetic engineering, offer advantages such as consistency, purity, and large-scale production. Key applications include pharmaceuticals, agriculture, and diagnostics, with growth fueled by research and development investments and regulatory approvals. Companies are focusing on innovation and cost reduction to expand their market share.

The Recombinant Proteins Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Abcam plc
  • Airway Therapeutics Inc.
  • Amgen Inc.
  • Aviva Systems Biology Corp.
  • Bio Techne Corp.
  • Bio Rad Laboratories Inc.
  • BPS Bioscience Inc.
  • Elabscience Biotechnology Inc.
  • Enzo Biochem Inc.
  • GenScript Biotech Corp.
  • Grifols SA
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • OriGene Technologies Inc.
  • Prospec Tany Technogene Ltd.
  • Proteintech Group Inc.
  • Sanofi SA
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Recombinant Proteins Market is a significant segment of the Biopharmaceuticals industry, valued at over USD100 billion. Pharma companies use recombinant technology to produce proteins in various expression systems, including bacterial cells, yeast & fungi, insect cells, and mammalian systems. These proteins find applications in the therapeutics segment, which dominates the market, with diabetes being a major indication. The International Diabetes Federation estimates that over 460 million people worldwide have diabetes, making it a lucrative market for protein-based treatments. Recombinant proteins are also used in the treatment of immune diseases, genetic disorders, and metabolic disorders. Neuroscience and immunology are other therapeutic areas that utilize recombinant proteins. The market is further segmented into therapeutics and services. The COVID-19 pandemic has accelerated the demand for recombinant proteins, with vaccines like Covovax and therapeutics for SARS-CoV2 being developed using this technology. The market also includes biosimilars and biologics for conditions like sclerosis, hemophilia, and granulomatous disease. Recombinant proteins are essential in the fight against chronic diseases, making this market an essential component of the global healthcare system.

Market Research Overview

The Recombinant Proteins Market is a significant and growing sector in the biotechnology industry, driven by the demand for antibody production and the development of biologics and biosimilars. Recombinant proteins are produced using gene libraries, host cell lines, and various vectors such as phage vectors. Companies like Aviva Systems Biology and American Cancer Society are at the forefront of antibody production using mammalian systems, while Sanofi, Phama, and Merck KGaA leverage bacterial cells, yeast & fungi, and insect cells. The therapeutics segment, which includes protein-based treatments for immune diseases, genetic disorders, metabolic disorders, and chronic diseases such as Alzheimer's disease, dementia, leukemia, HIV/AIDS, and cancer, dominates the market. Neuroscience and immunology are key application areas, with research funding and R&D budgets increasing for biopharmaceuticals. Recombinant technology is used to produce biomarkers for rare genetic diseases, such as Ayvakit for sclerosis, hemophilia, granulomatous disease, and others. The market also includes the production of biosimilars and vaccines like Covovax for SARS-CoV2 virus. The Mexican population, with its large and growing healthcare sector, is a significant market for recombinant proteins. The market is expected to continue growing, driven by the increasing prevalence of chronic diseases and the development of new therapeutics.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio
Document